MASS TORTS – APPLICATION TO DESIGNATE LITIGATION INVOLVING THE GADOLINIUM-BASED
DIAGNOSTIC CONTRAST AGENT OMNISCANTM AS A MASS TORT
Pursuant to Rule 4:38A and the Mass Tort Guidelines and Criteria for Designation (Directive #10-07), an application has been made to the Supreme Court, through the Administrative Director of the Courts, to designate all New Jersey state-court litigation involving the gadolinium-based diagnostic contrast agent Omniscantm, as a mass tort for centralized management and for assignment of that mass tort to the Middlesex Vicinage and Judge Jamie D. Happas. The application document is posted on the Judiciary’s Internet website at www.njcourtsonline.com.
Anyone wishing to comment on or object to this application should provide such comments or objections, with relevant supporting documentation, to Philip S. Carchman, P.J.A.D., Acting Administrative Director of the Courts, P. O. Box 037, Trenton, NJ 08625-0037, by March 1, 2008.
Philip S. Carchman, P.J.A.D.
Acting Administrative Director of the Courts
Dated: January 30, 2008